Synaptogenix (NASDAQ:TAOX) Upgraded to “Hold” at Wall Street Zen

Wall Street Zen upgraded shares of Synaptogenix (NASDAQ:TAOX) from a sell rating to a hold rating in a research report released on Saturday.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Synaptogenix in a research note on Tuesday, April 21st. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, Synaptogenix has a consensus rating of “Sell”.

Synaptogenix Stock Performance

NASDAQ:TAOX opened at $5.22 on Friday. The firm has a market capitalization of $38.99 million, a price-to-earnings ratio of -0.41 and a beta of 1.49. Synaptogenix has a 52-week low of $2.12 and a 52-week high of $11.98. The stock has a fifty day moving average of $5.39 and a 200 day moving average of $5.45.

Synaptogenix (NASDAQ:TAOX) last posted its quarterly earnings data on Wednesday, May 13th. The company reported $0.43 earnings per share (EPS) for the quarter. The business had revenue of $5.96 million for the quarter.

About Synaptogenix

Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer’s disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University.